Literature DB >> 26367457

Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for the treatment of patients with adenomyosis and prior abdominal surgical scars: A retrospective study.

Yu Xiong1, Yan Yue2, Lian Shui2, Franco Orsi3, Jia He4, Lian Zhang1,2.   

Abstract

OBJECTIVE: The aim of this paper was to retrospectively compare the therapeutic efficacy and adverse effects of ultrasound-guided high-intensity focused ultrasound (USgHIFU) treatment for adenomyotic patients with or without prior abdominal surgical scars.
METHODS: From January 2011 to March 2014, 534 patients with adenomyosis were referred for HIFU treatment. Among them, 118 patients had prior abdominal surgical scars, 416 patients did not have prior abdominal surgical scars. Contrast-enhanced MRI was used to evaluate the treatment outcomes. All the adverse effects were recorded.
RESULTS: All patients completed USgHIFU treatment. A fractional ablation of 74.8 ± 27.8% was achieved in the group of patients without abdominal scars; the fractional ablation was 75.6 ± 22.3% in the group of patients with prior abdominal surgical scars. No significant difference in fractional ablation between the two groups was observed (p > 0.05). The rate of skin burn in the group of patients with prior abdominal surgical scars was significantly higher than that in the group without abdominal scars (2.5% vs. 0.2%, p < 0.05), but it is still acceptable.
CONCLUSION: The prior abdominal surgical scars have no significant influence on the effectiveness of HIFU treatment for adenomyosis. The risk of skin burn is higher in patients with abdominal scars than without, but the incidence rate is still acceptable.

Entities:  

Keywords:  Abdominal surgical scars; adenomyosis; skin burn; ultrasound-guided high-intensity focused ultrasound (USgHIFU)

Mesh:

Year:  2015        PMID: 26367457     DOI: 10.3109/02656736.2015.1071436

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  1 in total

1.  High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma.

Authors:  Wei Lv; Tao Yan; Guojin Wang; Wei Zhao; Tao Zhang; Dinghua Zhou
Journal:  Ther Clin Risk Manag       Date:  2016-05-02       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.